-
When the University of Michigan Health System's chief risk officer arrived in 2001, he had already mapped out to institutional leaders an architecture for risk management and medical error disclosure that would dramatically change the system's liability expenses, as well as its approach to patient safety.
-
Some of the thorniest questions that IRBs face are those for which there are no clear-cut answers opinions may vary, arguments on both sides may be compelling, regulatory guidance may be scanty.
-
From a grassroots organization's efforts to make medical error disclosure and apology part of the U.S. health culture to more hospitals and other health care players are beginning to be aware of apology, and it would appear that more organizations agree that offering an institutional "I'm sorry" is the right thing to do.
-
A news analysis published in CANCER found that black patients with hepatocellular carcinoma (HCC), or liver cancer, have worse survival than patients of other races, even after receiving comparable treatments.
-
A growing number of clinics around the world are advertising therapeutic applications for stem cell treatments that have not been subjected to well-controlled trials.
-
Data on physicians prescribing is routinely purchased from pharmacies, with physicians identified through information purchased from the American Medical Association.
-
There is a growing focus on identifying a core set of quality metrics that can be used to improve both palliative and end-of-life care.
-
Comparative effectiveness research (CER) has the potential to improve outcomes and lower costs, but one key ethical concern is how to best convey to patients that they are participating in research.
-
While the vast majority of gamete donations are made anonymously, a growing number of countries are enacting laws allowing children access to identifying information about their gamete donor.
-
The Affordable Care Act invested significantly in comparative effectiveness research (CER), but at the same time, states that no decisions coming out of CER should determine what treatments are covered by insurers, notes Norman Daniels, PhD, professor of ethics and population health at Harvard School of Public Health in Boston, MA.
